Navigation Links
Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Date:3/13/2008

s license application

for PROVENGE(R) (sipuleucel-T).

-- Completed the target enrollment of 500 patients in the IMPACT study of

PROVENGE for advanced prostate cancer

-- Promoted Dr. Mark Frohlich to senior vice president of clinical

affairs and chief medical officer

-- Cancer Immunology, Immunotherapy publication on CD54 as surrogate

marker of antigen presenting cell activation

-- Data correlating the cumulative potency of PROVENGE to overall

survival presented at American Society of Clinical Oncology's

Genitourinary Symposium

-- Received European patent covering PROVENGE and Active Cellular

Immunotherapy (ACI) platform technology

"The most significant event in 2007 was the FDA advisory panel that voted in support of the substantial evidence of efficacy of PROVENGE for men with advanced prostate cancer," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We have begun 2008 by accelerating the final data analysis of the pivotal IMPACT study by approximately one year and we look forward to completing the interim analysis of this study in the second half of this year. We are committed to bringing what could be this first of its kind therapy to prostate cancer patients as soon as possible, as well as advancing other product candidates in our pipeline."

Conference Call Information

Dendreon will host a conference call today at 8:00 a.m. PT, 11:00 a.m. ET. To access the live call, dial 1-877-548-7901 (domestic) or +1-719-325-4844 (international). The call will also be audio webcast and will be available from the Company's website at http://www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 or +1-719-457-
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... WASHINGTON , May 4, 2015   ... announced updated interim data from Tocagen,s ongoing investigational ... Satellite Symposium of the American Association of Neurological ... Tumors, held May 1-2, 2015, in ... the company held a meeting with FDA and ...
(Date:5/4/2015)... Marianjoy Rehabilitation Hospital has ... hand impairments by acquiring the Armeo®Spring arm and ... site. , Secured through grant support of a ... option for patients with upper extremity weakness or ... of just four Illinois providers offering treatment with ...
(Date:5/1/2015)... , May 1, 2015 /PRNewswire/ - BioAmber Inc. ... sustainable chemicals, today announced that it has priced an underwritten ... at a price of $9.00 per share, and granted ... purchase up to an additional 585,000 shares of its ... be $35.1 million.  The offering is expected to close on ...
(Date:5/1/2015)... 1, 2015 A new report ... drugs will reach $22.4bn in 2019. That revenue forecast ... and Market Prospects 2015-2025 ,  published in ... is to provide forecasts and qualitative analyses of the ... and consultancy in London, UK . ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... 7 Cold season has settled in for the,winter ... cause for doctor,appointments and missed days of school and ... boost your immune system. And Immunity Enhanced Beverage is ... Recently introduced by Innovative Beverage Products, Immunity Enhanced,Beverage is ...
... Efficient Cold Chain VisibilityBEVERLY, Mass., Jan. 7 ... cold-chain visibility solutions, has launched the TempTale(R)4USB temperature ... model of the industry-leading TempTale4 product line provides ... proprietary software or readers. Sensitech is a wholly ...
... Ryan Burnette, Director of Alliance Biosciences will lead a ... 23, 2009. Dr. Burnette will be promoting the ... as a lynchpin to an effective biosecurity and biosafety ... a progressive country that has embraced the need for ...
Cached Biology Technology:Innovative Beverage Products Launches New Product Designed to Enhance the Body's Immune Defense 2Introducing Sensitech's TempTale(R)4USB Temperature Monitor 2Introducing Sensitech's TempTale(R)4USB Temperature Monitor 3Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar 2Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar 3
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... Your primary care physician may be your first choice ... new study led by researchers at the Johns Hopkins ... they may not be the best health care professionals ... physician perspectives on the causes of and solutions to ...
... their songs, most often heard in breeding season when males ... reports of whale songs occurring outside traditional breeding grounds have ... why. Humpbacks sing for their supper -- or ... The research, published December 19 in PLoS ONE , ...
... and you,re likely to see the dispersal of seedsdandelion tufts ... flying off with a dogwood fruit. You might even have ... recent graduate of the Virginia Institute of Marine Science, has ... environmentthe eelgrass beds of Chesapeake Bay. The studythe first to ...
Cached Biology News:Physicians admit feeling under qualified and lacking necessary education to treat obesity 2Multi-tasking whales sing while feeding, not just breeding 2Study reveals that animals contribute to seagrass dispersal 2Study reveals that animals contribute to seagrass dispersal 3
streptavidin, Alexa Fluor® 750–allophycocyanin conjugate (Alexa Fluor® 750–allophycocyanin streptavidin) *1 mg/mL*...
Template and primers for preparation of internal control spots...
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
Biology Products: